BIO KEY INTERNATIONAL INC	
Form 8-K June 27, 2018	
UNITED STATES	
SECURITIES AND EXCHANGE COMMISSION	
Washington, D.C. 20549	
FORM 8-K	
CURRENT REPORT	
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934	
Date of Report (Date of earliest event reported): June 22, 2018	
BIO-KEY INTERNATIONAL, INC.	
(Exact name of registrant as specified in its charter)	
Delaware 001-13463 41-1741861 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.	э.)
3349 Highway 138, Building A, Suite E	
Wall, NJ 07719	
(Address of principal executive offices) (Zip Code)	
(732) 359-1100	
(Registrant's telephone number, including area code)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securitie Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

BIO-key International, Inc. (the "Company,") held its Annual Meeting of Stockholders (the "Annual Meeting") on Friday, June 22, 2018. All holders of record of the Company's common stock, Series A-1 Preferred Stock, and Series B-1 Preferred Stock outstanding as of the close of business on April 25, 2018 were entitled to vote at the Special Meeting. Holders of Series A-1 Preferred Stock and Series B-1 Preferred Stock voted on an as converted to common stock basis together with holders of common stock as a single class. At the Annual Meeting, stockholders approved the proposals set forth below. Each of the proposals is more fully described in the Company's definitive proxy statement, which was filed with the Securities and Exchange Commission on April 30, 2018.

1. Proposal to elect the following nominees to serve as members of the Company's board of directors for a one-year term: Michael W. DePasquale, Wong Kwok Fong (Kelvin), Thomas Gilley, Thomas E. Bush, III, Pieter Knook, Robert J. Michel, Fabian Shin and Yao Jianhui. Each of the nominees were elected and the final voting results were as follows:

Name	Votes For	Withheld	Broker Non-Votes
Michael DePasquale	5,333,795	215,236	3,718,192
Wong Kwok Fong (Kelvin)	5,468,198	80,833	3,718,192
Thomas Gilley	5,447,369	101,662	3,718,192
Thomas E. Bush, III	5,447,591	101,440	3,718,192
Pieter Knook	5,468,615	80,416	3,718,192
Robert J. Michel	5,447,616	101,415	3,718,192
Fabian Shin	5,467,433	81,598	3,718,192
Yao Jianhui	5,468,301	80,730	3,718,192

2. Proposal to ratify the selection of Rotenberg Meril Solomon Bertiger & Guttilla, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2018. The proposal was approved and the final voting results were as follows:

Votes For Votes Against Abstentions Broker Non-Votes

9,050,441 45,505 171,277 0

3. Proposal to approve, on a non-binding and advisory basis, the compensation paid to the Company's named executive officers during the year ended December 31, 2017. The proposal was approved and the final voting results were as follows:

Votes For Votes Against Abstentions Broker Non-Votes

5,385,006 107,733 56,292 3,718,192

4.	Proposal to approve, on a non-binding and advisory basis, frequency of advisory approval of the compensation
paid to	o the Company's named executive officers. The stockholders approved, on a non-binding and advisory basis,
holdin	g the advisory vote on compensation paid to the Company's named executive officers every three years. The
final v	voting results were as follows:

One Year Two Years Three Years Abstentions

2,036,248 167,961 3,223,992 121,100

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-key International, Inc.

Date: June 27, 2018 By: /s/ Cecilia Welch

Cecilia Welch

Chief Financial Officer